stoxline Quote Chart Rank Option Currency Glossary
Voyager Therapeutics, Inc. (VYGR)
8.43  -0.2 (-2.32%)    05-17 16:00
Open: 8.67
High: 8.67
Volume: 529,954
Pre. Close: 8.63
Low: 8.35
Market Cap: 459(M)
Technical analysis
2024-05-17 4:49:26 PM
Short term     
Mid term     
Targets 6-month :  10.62 1-year :  12.41
Resists First :  9.1 Second :  10.62
Pivot price 8.46
Supports First :  7.96 Second :  7.26
MAs MA(5) :  8.51 MA(20) :  8.24
MA(100) :  8.45 MA(250) :  8.76
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  66.5 D(3) :  68.2
RSI RSI(14): 49.5
52-week High :  14.34 Low :  6.05
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ VYGR ] has closed above bottom band by 46.8%. Bollinger Bands are 40.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.68 - 8.73 8.73 - 8.76
Low: 8.24 - 8.29 8.29 - 8.34
Close: 8.35 - 8.43 8.43 - 8.51
Company Description

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 17 May 2024
Voyager Therapeutics (NASDAQ:VYGR) Earns Outperform Rating from Oppenheimer - Defense World

Thu, 16 May 2024
Wedbush Weighs in on Voyager Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:VYGR) - Defense World

Thu, 16 May 2024
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the ... - GlobeNewswire

Wed, 15 May 2024
Investors in Voyager Therapeutics (NASDAQ:VYGR) have unfortunately lost 76% over the last three years - Yahoo New Zealand News

Tue, 14 May 2024
Earnings call: Voyager Therapeutics advances Alzheimer's and gene therapy -

Tue, 14 May 2024
Voyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript Highlights: Strategic Partnerships and Pipeline ... -

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 54 (M)
Shares Float 37 (M)
Held by Insiders 16.9 (%)
Held by Institutions 54.6 (%)
Shares Short 4,210 (K)
Shares Short P.Month 3,330 (K)
Stock Financials
EPS 2.97
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.36
Profit Margin 52.9 %
Operating Margin 60 %
Return on Assets (ttm) 29.8 %
Return on Equity (ttm) 89.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 4.59
EBITDA (p.s.) 2.32
Qtrly Earnings Growth 0 %
Operating Cash Flow 78 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio 2.83
PEG Ratio 0
Price to Book value 1.56
Price to Sales 1.83
Price to Cash Flow 5.88
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android